← Back to Search

Radiation Therapy

AI-Directed Radiation Therapy for Lung Cancer

N/A

Recruiting

Led By Mohamed E Abazeed, MD, PhD

Research Sponsored by Northwestern University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients must be age >= 18 years

Patients must exhibit an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial tests AI to help improve dose prescription for lung radiation therapy to help reduce local recurrence.

Who is the study for?

Adults (18+) with primary lung cancer or a few metastatic tumors in the lungs, able to perform daily activities (ECOG 0-2), and not pregnant can join. They must understand and sign consent. Excluded are those with prior overlapping radiotherapy, unresolved thoracic toxicities from past treatments, concurrent investigational drugs, other interfering malignancies, or uncontrolled illnesses.Check my eligibility

What is being tested?

The RAD-AI study is testing if AI can improve dose recommendations during SBRT for lung cancer treatment. It aims to see if personalized AI predictions lead to better outcomes by reducing local recurrence of the disease while minimizing damage to healthy tissue.See study design

What are the potential side effects?

SBRT may cause side effects like skin irritation at the treatment site, fatigue, shortness of breath due to inflammation in the lungs (pneumonitis), chest pain, coughing up blood (hemoptysis), difficulty swallowing (esophagitis), and potential damage to nearby organs.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I can take care of myself and am up and about more than half of my waking hours.

Select...

I can understand and am willing to sign the consent form.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

LFS

Local failure free survival (LFS)

Secondary outcome measures

Dose recommended

Incidence of adverse events

Progression-free survival (PFS)

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (AI-directed analysis, SBRT)Experimental Treatment7 Interventions

Patients undergo radiation planning with AI-directed analysis for dose recommendations with Deep Profiler + iGray software on study. Patients then undergo SBRT on study. Patients also undergo PET, CT, MRI, and/or x-ray imaging during screening and follow-up.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Positron Emission Tomography

2008

Completed Phase 2

~2240

Stereotactic Body Radiation Therapy

2012

Completed Phase 2

~780

Computed Tomography

2017

Completed Phase 2

~2720

Magnetic Resonance Imaging

2017

Completed Phase 3

~1190

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Northwestern UniversityLead Sponsor

1,589 Previous Clinical Trials

917,017 Total Patients Enrolled

Varian Medical SystemsIndustry Sponsor

59 Previous Clinical Trials

3,709 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,672 Previous Clinical Trials

40,926,371 Total Patients Enrolled

Media Library

Stereotactic Body Radiation Therapy (Radiation Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05802186 — N/A

Non-Small Cell Lung Cancer Research Study Groups: Treatment (AI-directed analysis, SBRT)

Non-Small Cell Lung Cancer Clinical Trial 2023: Stereotactic Body Radiation Therapy Highlights & Side Effects. Trial Name: NCT05802186 — N/A

Stereotactic Body Radiation Therapy (Radiation Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05802186 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still vacancies for volunteers to join this trial?

"As reported on clinicaltrials.gov, the recruitment for this study has ended as of March 24th 2023. Initially posted on May 31st 2023, this trial is no longer searching for participants; however, there are 6463 other trials that require patients at present time."

Answered by AI

What is the fundamental purpose of this clinical experiment?

"Over a duration of two years, the research team will evaluate this study's primary objective of Overall Survival. Secondary metrics include evaluating Respiratory Function via RTOG Pulmonary Function Test Toxicity Scale, Incidence of Adverse Events through National Cancer Institute-Common Terminology Criteria for Adverse Events v5.0., and assessing physician adherence to prescribed doses as recommended by Deep Profiler +iGray software over one to two weeks during SBRT treatment."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study

2023. "Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05802186.